- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Veradigm is a health information services business based in the US. Veradigm shares (MDRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.75 – a decrease of 4.51% over the previous week. Veradigm employs 8,000 staff and has a trailing 12-month revenue of around $1.5 billion.
Our top picks for where to buy Veradigm stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
How to buy Veradigm stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MDRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Veradigm stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Veradigm stock price (NASDAQ: MDRX)
Use our graph to track the performance of MDRX stocks over time.Veradigm shares at a glance
Latest market close | $9.75 |
---|---|
52-week range | $5.01 - $11.80 |
50-day moving average | $9.96 |
200-day moving average | $9.15 |
Wall St. target price | $12.75 |
PE ratio | 11.0795 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.88 |
Is it a good time to buy Veradigm stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Veradigm price performance over time
Historical closes compared with the close of $9.5 from 2024-12-17
1 week (2024-12-12) | -6.95% |
---|---|
1 month (2024-11-19) | -9.00% |
3 months (2024-09-19) | -3.46% |
6 months (2024-06-18) | -1.04% |
1 year (2023-12-19) | -3.46% |
---|---|
2 years (2022-12-19) | -46.72% |
3 years (2021-12-17) | 18.54 |
5 years (2019-12-19) | 9.75 |
Is Veradigm stock undervalued or overvalued?
Valuing Veradigm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veradigm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Veradigm's P/E ratio
Veradigm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Veradigm shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Veradigm's PEG ratio
Veradigm's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4237. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Veradigm's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Veradigm's EBITDA
Veradigm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $115.4 million.
The EBITDA is a measure of a Veradigm's overall financial performance and is widely used to measure a its profitability.
Veradigm financials
Revenue TTM | $1.5 billion |
---|---|
Operating margin TTM | 16.59% |
Gross profit TTM | $738.3 million |
Return on assets TTM | 2.16% |
Return on equity TTM | 8.93% |
Profit margin | 3.97% |
Book value | $10.77 |
Market Capitalization | $1 billion |
TTM: trailing 12 months
Veradigm share dividends
We're not expecting Veradigm to pay a dividend over the next 12 months.
Veradigm share price volatility
Over the last 12 months, Veradigm's shares have ranged in value from as little as $5.01 up to $11.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veradigm's is 0.604. This would suggest that Veradigm's shares are less volatile than average (for this exchange).
Veradigm overview
Veradigm Inc. , a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc.
Frequently asked questions
nullWhat percentage of Veradigm is owned by insiders or institutions?
Currently 1.117% of Veradigm shares are held by insiders and 23.245% by institutions. How many people work for Veradigm?
Latest data suggests 8,000 work at Veradigm. When does the fiscal year end for Veradigm?
Veradigm's fiscal year ends in December. Where is Veradigm based?
Veradigm's address is: 222 Merchandise Mart Plaza, Chicago, IL, United States, 60654 What is Veradigm's ISIN number?
Veradigm's international securities identification number is: US01988P1084 What is Veradigm's CUSIP number?
Veradigm's Committee on Uniform Securities Identification Procedures number is: 01988P108
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question